Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 547 | 90 | 440 |
| Samples | 486 | 82 | 396 |
| Peptides | 411 | 61 | 350 |
Function
MED14 · Mediator complex subunit 14
The activation of gene transcription is a multistep process that is triggered by factors that recognize transcriptional enhancer sites in DNA. These factors work with co-activators to direct transcriptional initiation by the RNA polymerase II apparatus. The protein encoded by this gene is a subunit of the CRSP (cofactor required for SP1 activation) complex, which, along with TFIID, is required for efficient activation by SP1. This protein is also a component of other multisubunit complexes e.g. thyroid hormone receptor-(TR-) associated proteins which interact with TR and facilitate TR function on DNA templates in conjunction with initiation factors and cofactors. This protein contains a bipartite nuclear localization signal. This gene is known to escape chromosome X-inactivation. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000324817 | O60244 | 547 | 411 |
Gene Properties
Recurrent Mutations
All 412 amino-acid changes on canonical ENST00000324817 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MED14 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MED14 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Endometrial Carcinoma | 5/42 12% | 44/612 7% |
| Melanoma | 3/210 1% | 61/1899 3% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Squamous Cell Lung Carcinoma | 6/57 11% | 12/810 1% |
| Colorectal Carcinoma | 11/143 8% | 49/3239 2% |
| Cervical Carcinoma | 0/35 0% | 8/422 2% |
| Burkitts Lymphoma | 3/32 9% | 1/196 1% |
| Non-Small Cell Lung Carcinoma | 12/304 4% | 14/1390 1% |
| Gastric Carcinoma | 1/74 1% | 26/1809 1% |
| Hepatocellular Carcinoma | 1/46 2% | 25/2210 1% |
| Neuroendocrine Tumour | 4/154 3% | 4/577 1% |
| Germ Cell Tumour | 1/25 4% | 1/169 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Bladder Carcinoma | 0/58 0% | 10/956 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 16/1592 1% |
| Other Solid Cancers | 0/94 0% | 15/1515 1% |
| Head and Neck Carcinoma | 2/85 2% | 13/1574 1% |
| Kidney Carcinoma | 0/85 0% | 17/1862 1% |
| Non-Cancerous | 1/104 1% | 7/830 1% |
| Other Sarcomas | 0/69 0% | 6/699 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Breast Carcinoma | 5/144 3% | 19/3264 1% |
| Glioma | 0/52 0% | 14/2127 1% |
| Ovarian Carcinoma | 5/109 5% | 2/998 0% |
| Esophageal Carcinoma | 2/23 9% | 3/769 0% |
| Plasma Cell Myeloma | 1/44 2% | 1/305 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Biliary Tract Carcinoma | 1/54 2% | 3/950 0% |
Mutation Distribution
Where MED14 is mutated · all tissues, split by cell line vs tissue
How many mutations in MED14 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 547 mutations in MED14
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|